Trilaciclib clinical trials
Trilaciclib is named as an intervention in 14 current clinical trials in our China, USA and Spain registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (3). The most-studied condition is Myelosuppression.
How Trilaciclib works
All drug targets →- Cyclin-dependent kinase 4 inhibitor InhibitorTarget: CDK4 cyclin dependent kinase 4✓ In ChEMBL and the Guide to Pharmacology
- Cyclin-dependent kinase 6 inhibitor InhibitorTarget: CDK6 cyclin dependent kinase 6✓ In ChEMBL and the Guide to Pharmacology
- Triple-negative breast carcinomaPhase 3
- Urothelial carcinomaPhase 3
- HER2 positive breast carcinomaPhase 2
- Breast cancerPhase 2
- Diffuse large B-cell lymphomaPhase 2
- Esophageal squamous cell carcinomaPhase 2
- Exocrine pancreatic carcinomaPhase 2
- Leptomeningeal metastasisPhase 2
- Non-small cell lung carcinomaPhase 2
- OsteosarcomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3894860, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9626, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Trilaciclib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Trilaciclib
- ChEMBL
- CHEMBL3894860
- DrugBank
- DB15442
- PubChem CID
- 68029831
- CAS number
- 1374743-00-6
- FDA UNII
- U6072DO9XG
- Wikidata
- Q105592965
- Wikipedia
- Trilaciclib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Trilaciclib
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Trilaciclib
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Myelosuppression | 3 |
| Breast Cancer | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Limited Stage Small Cell Lung Cancer | 1 |
| Osteosarcoma | 1 |
| Lung Cancer, Small Cell | 1 |
| Endometrial Cancer | 1 |
| Cervical Cancer | 1 |
| Breast Neoplasms | 1 |
| Ewing Sarcoma | 1 |
| ESCC | 1 |
| Head and Neck Cancer Squamous Cell Carcinoma | 1 |
| Non-small Cell Lung Cancer | 1 |
| DLBCL | 1 |
| Extensive-stage Small-cell Lung Cancer | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 12 | 8 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Spain | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Trilaciclib trials
How many clinical trials are testing Trilaciclib?
14 current trials in our China, USA and Spain registers name Trilaciclib (also registered as G1T28) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Trilaciclib trials recruiting patients?
Yes. 9 of the 14 trials are recruiting: 8 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Trilaciclib clinical trials?
Sun Yat-sen University (3), Pharmacosmos A/S (2), Peking University People's Hospital (1) and Shanghai Chest Hospital (1), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trilaciclib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trilaciclib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trilaciclib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.